ImmuPharma PLC - ESG Rating & Company Profile powered by AI
Alternative corporations in the rating industry group for ImmuPharma PLC are displayed. The ESG score includes 17 UN SDGs including: 'No Poverty', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'. Check the bottom of this page for potential risks for ImmuPharma PLC based on industry, geography and size.
ImmuPharma PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 0.0, social score of 5.3 and governance score of 5.3.
3.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1144 | Veerhealth Care Ltd | 3.6 | Medium |
| 1144 | iStreet Network Ltd | 3.6 | Medium |
| 1186 | ImmuPharma PLC | 3.5 | Medium |
| 1186 | CRISPR Therapeutics AG | 3.5 | Medium |
| 1186 | Catalent Inc | 3.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ImmuPharma PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ImmuPharma PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes ImmuPharma PLC report the average age of the workforce?
Sign up for free to unlockDoes ImmuPharma PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ImmuPharma PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes ImmuPharma PLC disclose cybersecurity risks?
Sign up for free to unlockDoes ImmuPharma PLC offer flexible work?
Sign up for free to unlockDoes ImmuPharma PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ImmuPharma PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ImmuPharma PLC conduct supply chain audits?
Sign up for free to unlockDoes ImmuPharma PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ImmuPharma PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes ImmuPharma PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes ImmuPharma PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ImmuPharma PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ImmuPharma PLC disclose water use targets?
Sign up for free to unlockDoes ImmuPharma PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid ImmuPharma PLC have a product recall in the last two years?
Sign up for free to unlockDoes ImmuPharma PLC disclose incidents of discrimination?
Sign up for free to unlockDoes ImmuPharma PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ImmuPharma PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ImmuPharma PLC disclose parental leave metrics?
Sign up for free to unlockDoes ImmuPharma PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ImmuPharma PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ImmuPharma PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes ImmuPharma PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ImmuPharma PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ImmuPharma PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ImmuPharma PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes ImmuPharma PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ImmuPharma PLC disclose its waste policy?
Sign up for free to unlockDoes ImmuPharma PLC report according to TCFD requirements?
Sign up for free to unlockDoes ImmuPharma PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ImmuPharma PLC disclose energy use targets?
Sign up for free to unlockDoes ImmuPharma PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ImmuPharma PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ImmuPharma PLC
These potential risks are based on the size, segment and geographies of the company.
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.